In liver transplant, during anti-viral therapy for hepatitis C virus (HCV) recurrence, the immunosuppressant levels should be monitored to prevent both toxicity and rejection. Sofosbuvir (SOF) has been used within compassionate programs for HCV recurrence and, according to pharmacokinetic analyses, is not supposed to have significant pharmacological interactions with tacrolimus (Tac) or ciclosporin.1 This was reported in the review article by Koff recently published.2 We treated eight transplant recipients with SOF/ribavirin (RBV) for a severe HCV recurrence, and observed unexpected Tac/ciclosporin reduction during SOF.
Vukotic R, Morelli M, Pinna AD, Margotti M, Foschi FG, Loggi E, et al. (2014). Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 40, 405-405 [10.1111/apt.12853].
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients.
VUKOTIC, RANKA;PINNA, ANTONIO DANIELE;MARGOTTI, MARZIA;LOGGI, ELISABETTA;BERNARDI, MAURO;ANDREONE, PIETRO
2014
Abstract
In liver transplant, during anti-viral therapy for hepatitis C virus (HCV) recurrence, the immunosuppressant levels should be monitored to prevent both toxicity and rejection. Sofosbuvir (SOF) has been used within compassionate programs for HCV recurrence and, according to pharmacokinetic analyses, is not supposed to have significant pharmacological interactions with tacrolimus (Tac) or ciclosporin.1 This was reported in the review article by Koff recently published.2 We treated eight transplant recipients with SOF/ribavirin (RBV) for a severe HCV recurrence, and observed unexpected Tac/ciclosporin reduction during SOF.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
